PCSA · Processa Pharmaceuticals, Inc. · Fails to Deliver
$1.99
-0.17 (-7.87%)
At close · Sep 9
Going-concern doubt
— cleared Aug 14, 2026
The latest filing states the doubt was alleviated.
“Following our acquisition of Vidya and closing of the related $200 million gross private placement (from which we received net proceeds of $183.3 million) on July 30, 2026, we believe our cash and cash equivalents will be sufficient to satisfy our cash requirements over the next 12 months and beyond. This represents a material change from what we reported in our 2025 Form 10-K that disclosed substantial doubt of our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$5.56M
Shares
2.79M
Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.
Fails to Deliver History
| Settlement Date | Quantity | Price | Value |
|---|---|---|---|
| 2026-08-13 | 1,933 | $2.56 | $4,948 |
| 2026-08-12 | 126 | $2.63 | $331 |
| 2026-08-10 | 6,165 | $2.57 | $15,844 |
| 2026-08-07 | 340 | $2.30 | $782 |
| 2026-08-06 | 1,640 | $2.19 | $3,592 |
| 2026-08-05 | 2,240 | $2.12 | $4,749 |
| 2026-08-04 | 502 | $2.13 | $1,069 |
| 2026-08-03 | 2,724 | $2.15 | $5,857 |
| 2026-07-31 | 15,144 | $2.04 | $30,894 |
| 2026-07-30 | 74,470 | $2.03 | $151,174 |
| 2026-07-29 | 3,143 | $3.05 | $9,586 |
| 2026-07-28 | 793 | $2.59 | $2,054 |
| 2026-07-27 | 2,226 | $2.60 | $5,788 |
| 2026-07-24 | 3,684 | $2.87 | $10,573 |
| 2026-07-23 | 689 | $2.54 | $1,750 |
| 2026-07-21 | 749 | $2.22 | $1,663 |
| 2026-07-20 | 225 | $2.31 | $520 |
| 2026-07-15 | 8,432 | $2.29 | $19,309 |
| 2026-07-10 | 490 | $1.97 | $965 |
| 2026-07-09 | 876 | $1.89 | $1,656 |
| 2026-07-07 | 740 | $2.10 | $1,554 |
| 2026-07-02 | 1,904 | $1.96 | $3,732 |
| 2026-06-26 | 11 | $1.89 | $21 |
| 2026-06-25 | 15 | $1.93 | $29 |
| 2026-06-12 | 1,958 | $2.37 | $4,640 |
Showing 1–25 of 25 settlements
Key facts
CIK
1533743
CUSIP
74275C403
13F (30d)
12 filings
12 filers
Visit website
Investor relations